NasdaqGS:SYREBiotechs
Is Spyre Therapeutics (SYRE) Using Faster RA Trial Timelines To Redefine Its Autoimmune Strategy?
Spyre Therapeutics, Inc. recently reported it has completed recruitment for the rheumatoid arthritis (RA) sub-study of its SKYWAY Phase 2 trial of SPY072, accelerating the expected topline readout to the third quarter of 2026, with additional proof-of-concept data for psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) anticipated in the fourth quarter.
The company is positioning SPY072, an extended half-life TL1A-targeting antibody, as a potentially more convenient rheumatic...